199 related articles for article (PubMed ID: 35098564)
1. Protein signatures to distinguish aggressive from indolent prostate cancer.
Garcia-Marques F; Liu S; Totten SM; Bermudez A; Tanimoto C; Hsu EC; Nolley R; Hembree A; Stoyanova T; Brooks JD; Pitteri SJ
Prostate; 2022 Apr; 82(5):605-616. PubMed ID: 35098564
[TBL] [Abstract][Full Text] [Related]
2. Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.
Li QK; Chen J; Hu Y; Höti N; Lih TM; Thomas SN; Chen L; Roy S; Meeker A; Shah P; Chen L; Bova GS; Zhang B; Zhang H
Sci Rep; 2021 Sep; 11(1):18936. PubMed ID: 34556748
[TBL] [Abstract][Full Text] [Related]
3. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.
Kim Y; Ignatchenko V; Yao CQ; Kalatskaya I; Nyalwidhe JO; Lance RS; Gramolini AO; Troyer DA; Stein LD; Boutros PC; Medin JA; Semmes OJ; Drake RR; Kislinger T
Mol Cell Proteomics; 2012 Dec; 11(12):1870-84. PubMed ID: 22986220
[TBL] [Abstract][Full Text] [Related]
4. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.
Al-Ruwaili JA; Larkin SE; Zeidan BA; Taylor MG; Adra CN; Aukim-Hastie CL; Townsend PA
Cancer Genomics Proteomics; 2010; 7(2):93-103. PubMed ID: 20335524
[TBL] [Abstract][Full Text] [Related]
5. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Neuhaus J; Schiffer E; von Wilcke P; Bauer HW; Leung H; Siwy J; Ulrici W; Paasch U; Horn LC; Stolzenburg JU
PLoS One; 2013; 8(6):e67514. PubMed ID: 23826311
[TBL] [Abstract][Full Text] [Related]
6. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness.
Liu Y; Chen J; Sethi A; Li QK; Chen L; Collins B; Gillet LC; Wollscheid B; Zhang H; Aebersold R
Mol Cell Proteomics; 2014 Jul; 13(7):1753-68. PubMed ID: 24741114
[TBL] [Abstract][Full Text] [Related]
7. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
Fredolini C; Liotta LA; Petricoin EF
Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
[TBL] [Abstract][Full Text] [Related]
8. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
9. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
[TBL] [Abstract][Full Text] [Related]
10. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
[TBL] [Abstract][Full Text] [Related]
11. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
12. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.
Kim Y; Jeon J; Mejia S; Yao CQ; Ignatchenko V; Nyalwidhe JO; Gramolini AO; Lance RS; Troyer DA; Drake RR; Boutros PC; Semmes OJ; Kislinger T
Nat Commun; 2016 Jun; 7():11906. PubMed ID: 27350604
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer diagnosis and characterization with mass spectrometry imaging.
Kurreck A; Vandergrift LA; Fuss TL; Habbel P; Agar NYR; Cheng LL
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):297-305. PubMed ID: 29209003
[TBL] [Abstract][Full Text] [Related]
14. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing indolent from aggressive prostate cancer.
Culig Z
Recent Results Cancer Res; 2014; 202():141-7. PubMed ID: 24531788
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer proteomics.
Masters JR
OMICS; 2011 Mar; 15(3):169-71. PubMed ID: 21319990
[TBL] [Abstract][Full Text] [Related]
18. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.
Khoo A; Liu LY; Nyalwidhe JO; Semmes OJ; Vesprini D; Downes MR; Boutros PC; Liu SK; Kislinger T
Nat Rev Urol; 2021 Dec; 18(12):707-724. PubMed ID: 34453155
[TBL] [Abstract][Full Text] [Related]
19. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
20. The Thoc1 ribonucleoprotein and prostate cancer progression.
Chinnam M; Wang Y; Zhang X; Gold DL; Khoury T; Nikitin AY; Foster BA; Li Y; Bshara W; Morrison CD; Payne Ondracek RD; Mohler JL; Goodrich DW
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25296641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
